KAPA ▼ -4.4% - Kairos Pharma, Ltd. $KAPA - Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer 06-OCT-2026 07:33 AM ET